Lip’ral

H.C. Wainwright’s Corey Davis believes that what differentiates Lipocine Inc (NASDAQ: LPCN) from its competitors is the company’s oral drug delivery technology, called “Lip’ral”. Davis initiated coverage of the company with a Buy rating and price target of $25....